The IN-ARMOR project registers a new patent on novel immune system inducers
The consortium of the IN-ARMOR project, funded by European Union´s Horizon Europe research and innovation programme under grant agreement No 101080889, has registered a new patent titled “Novel small molecules as immune system inducers”, addressing the need for new therapeutic approaches that strengthen the body’s innate immune defences and reduce reliance on conventional antibiotics in the context of antimicrobial resistance (AMR). This achievement represents a significant step toward the development of host-directed therapies that enhance immune defence, support epithelial barrier function, and improve protection against infection and inflammation.
Project Context
The IN-ARMOR project brings together 16 partners from 10 countries, among which are universities, research centers, companies and public entities. Its aim is to introduce a new class of immune system inducers capable of enhancing the body’s own innate defense mechanisms to combat Antimicrobial Resistance (AMR). Since its launch in 2023, the consortium has been working on epigenetic enhancement of innate immunity, computer-aided drug design, and nanotechnology-based delivery systems to drive innovative solutions in the healthcare sector and the fight against antimicrobial resistance (AMR).
About the Patent
- Official title: Novel small molecules as immune system inducers
- Submission date: December 24th 2025
- Applicant organisation: Akthelia Pharmaceuticals, University of Iceland, Enamine, University of Groningen
- Technical summary: The patent covers novel small-molecule immune system inducers that act on host cellular regulatory pathways to strengthen innate immune defence, improve epithelial barrier function, and modulate inflammation in a controlled manner.
Relevance and Impact
This innovation has the potential to deliver new host-directed therapies for infectious and inflammatory diseases, particularly those involving mucosal surfaces and epithelial barrier dysfunction. It directly supports European AMR strategies, Horizon Europe health priorities, and the need for alternatives to traditional antibiotics, while strengthening the consortium’s position as a reference in innate immunity-based drug discovery.
“This patent reflects the core ambition of IN-ARMOR: to develop innovative therapies that help the body defend itself more effectively against infection while reducing dependence on antibiotics.” Egill Másson, CEO, Akthelia Pharmaceuticals.
